Taighde ar chomhdhéanamh coirp & meitibileacht.
An tseilf GLP-1 agus gach rud ina timpeall: semaglutide, tirzepatide agus retatrutide i bpinn réamhlíonta, mar aon le tesamorelin, AOD9604, tesofensine agus na meascáin mheitibileacha. Is í seo an grúpa is mó a bhfuil staidéar déanta uirthi sa chatalóg seo, agus clúdaíonn ár ndeasc thaighde na trialacha taobh thiar de gach comhdhúil seachas achoimre a dhéanamh ar an margaíocht.
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%Sula n-ordaíonn tú
GLP-1Tirzepatide: what SURMOUNT-1 and SURMOUNT-2 actually showed
Two 72-week placebo-controlled trials, 3,477 participants between them — one in obesity without diabetes, one in obesity with type 2 diabetes. The published weight-loss figures, dose by dose, and where the data stop.
PerformanceExercise mimetics: what AICAR, SLU-PP-332 and 5-Amino-1MQ have actually done, and in what species
One of these three has been given to 3,080 humans — and the trial was stopped for futility. The other two have never been given to a human at all. All three are sold on the same phrase, and the phrase comes from one mouse treadmill experiment in 2008.
MetabolicTesofensine: a phase 2 result that never became a phase 3 paper
The 2008 Lancet trial is real, and the numbers in it are large. What followed is the part nobody quotes — an Expression of Concern from the journal, no published phase 3 anywhere in the indexed literature, and no approval in the EU or the US.